Report Categories
View AllRecent Articles
View All
QURE uniQure NV shares fall 731 despite Q4 2025 EPS beating analyst estimates by 337
GNRC Generac Holdlings posts 328 percent Q1 2026 EPS beat shares see modest gain today
SES SES AI reports wider than expected Q1 2026 loss shares fall 19 percent on cautious investor sentiment
What Alliance Res ARLP does that makes it resilient Volatility Increases 20260508
EU Green Economy Doubles Output in Less Than a Decade as Solar Energy Surges
Bitcoin Consolidates as Equity Markets Rally in Weekly Trading Session
Google Redesigns Homepage Search Box to Integrate AI Features
Deutsche Bank Lifts Equinix Price Target on Data Center Growth Prospects
US Faces 28 Trillion Net Foreign Liability Gap as Fed Data Shows Surging Overseas Investment in America
Alphabet Hosts Q1 2026 Earnings Call Investors Eye Cloud and AI Growth
NNOX Q4 2025 Earnings EPS Misses Estimates Amid Lack of Reported Revenue
CIMN Q1 2026 Earnings EPS Beats Estimates Amid Steady Performance
FRAF Q1 2026 Earnings EPS Surpasses Estimates by 828 Stock Edges Lower
RCKT Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Continues Clinical Progress
GEL Q1 2026 Earnings Significant EPS Miss on Weak Operating Performance
Diamondrock Hospitality DRH Q1 2026 Earnings EPS Surges Past Estimates Despite Undisclosed Revenue
FCO Dips 116 as abrdn Global Income Fund Encounters Mild Selling Pressure
WaterBridge Infrastructure WBI Faces Pressure Price Drops Nearly 5
Five Star Bancorp FSBC Consolidates Near Support as Banking Sector Faces Mixed Signals
aTyr Pharma ATYR Slides 27 Approaching Key Support at 048
Flag Ship Acquisition Corp Rights FSHPR Stays RangeBound Near 008 Amid Quiet Trading
HLI Q1 2026 Earnings EPS Misses Estimates Amid Modest Stock Uptick
VLN Q1 2026 Earnings EPS Surprises to the Upside Despite Revenue Uncertainties
Trimble Q1 2026 Earnings EPS Surpasses Estimates as Stock Trades Higher
GLRE Q1 2026 Earnings Strong Profitability Drives Positive Market Response
BKV Q1 2026 Earnings EPS Misses Estimates as Revenue Details Remain Undisclosed
Dianthus Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Highlights Cost Discipline